<DOC>
	<DOCNO>NCT01347788</DOCNO>
	<brief_summary>Cabozantinib ( XL184 ) new drug develop treat cancer . Cabozantinib work block `` angiogenesis , '' growth new blood vessel , tumor . This similar several cancer drug work addition Cabozantinib also block pathway may responsible allow cancer cell become resistant `` anti-angiogenic '' treatment . So far cabozantinib investigated treat brain cancer rare form thyroid cancer . This study explore low dos cabozantinib goal find effective , safe , tolerable dose without undesirable side effect .</brief_summary>
	<brief_title>Cabozantinib ( XL184 ) Men With Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>Cabozantinib take mouth daily . The first five treatment cycle 21 day . All cycle 42 day long . Patients keep diary record study drug dose . During screen phase patient receive physical exam , blood urine test , bone scan , CT abdomen pelvis , MRI scan total body . On Day 1 cycle patient receive physical exam blood urine test . Bone scan , CT MRI scan perform start cycle 3 5 , repeat every 12 week . Patients continue receive study treatment long receiving benefit treatment , experience severe unmanageable side effect , disease get bad .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Histologically confirm prostate adenocarcinoma Bone metastases confirm bone scan Current androgen deprivation therapy Castrationresistant disease base progression bone and/or PSA progression Recovered toxicity relate prior treatment , except alopecia , lymphopenia , nonclinically significant adverse event Life expectancy great 3 month Normal organ marrow function Capable understand comply protocol requirement Agree use medically accept method contraception Able swallow capsule More two prior chemotherapy regimens metastatic prostate cancer Known untreated , symptomatic uncontrolled brain metastasis Serious unhealed wound Treatment anticoagulants Previously identify allergy hypersensitivity component study treatment formulation History different malignancy unless diseasefree least 5 year , basal squamous cell carcinoma skin Current antiretroviral therapy Uncontrolled hypertension Uncontrolled intercurrent illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Castration Resistant</keyword>
	<keyword>Bone Metastases</keyword>
</DOC>